Drug reference
cholera vaccine
live attenuated vaccine · vaccine
live attenuated vaccinevaccine
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
A live attenuated oral cholera vaccine designed to prevent cholera caused by serogroup O1. Efficacy was demonstrated at 90% 10 days post-vaccination and 80% at 3 months.
Indications
prevention of cholera caused by serogroup O1 for adults 18 through 64 years of age traveling to cholera-affected areas. (Vaxchora is a specific brand of this type)Prevention of clinical cholera diseaseTo tide over an epidemic
Dosing
- Adult
- a single, oral liquid dose of approximately 3 fl oz at least 10 days before travel to a cholera-affected area
Pharmacokinetics
Onset
2–3 weeks (for immunity to develop)
Duration
6 months
Side effects
Common
Transient local sorenessLow grade feverAches and pains (lasting 1–2 days)
Serious
- Neurological complications (rare)
Related guidelines
Diabetic foot — clinical management
MOHFW · Endocrinology · 2021
Primary prevention of cardiovascular disease
AHA · Cardiology · 2019
Cardiovascular disease prevention
ESC · Cardiology · 2021
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Coeliac disease
OTHER · Gastroenterology · 2016
Other live attenuated vaccine drugs
Ask House about cholera vaccine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team